Parkwood LLC reduced its position in shares of Medtronic PLC (NYSE:MDT) by 16.6% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 3,487 shares of the medical technology company’s stock after selling 692 shares during the period. Parkwood LLC’s holdings in Medtronic PLC were worth $309,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. Jackson Grant Investment Advisers Inc. increased its position in Medtronic PLC by 0.3% in the first quarter. Jackson Grant Investment Advisers Inc. now owns 2,920 shares of the medical technology company’s stock worth $235,000 after buying an additional 9 shares during the period. Hudock Capital Group LLC increased its position in Medtronic PLC by 0.6% in the first quarter. Hudock Capital Group LLC now owns 2,184 shares of the medical technology company’s stock worth $175,000 after buying an additional 12 shares during the period. Delta Asset Management LLC TN increased its position in Medtronic PLC by 0.4% in the first quarter. Delta Asset Management LLC TN now owns 3,713 shares of the medical technology company’s stock worth $299,000 after buying an additional 13 shares during the period. Bollard Group LLC increased its position in Medtronic PLC by 0.4% in the first quarter. Bollard Group LLC now owns 3,637 shares of the medical technology company’s stock worth $293,000 after buying an additional 14 shares during the period. Finally, Triangle Securities Wealth Management increased its position in Medtronic PLC by 0.3% in the second quarter. Triangle Securities Wealth Management now owns 4,396 shares of the medical technology company’s stock worth $390,000 after buying an additional 15 shares during the period. 80.49% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Medtronic PLC (MDT) traded down 0.06% during midday trading on Tuesday, hitting $79.54. 1,756,145 shares of the stock were exchanged. Medtronic PLC has a one year low of $69.35 and a one year high of $89.72. The stock’s 50-day moving average price is $84.48 and its 200 day moving average price is $83.39. The stock has a market cap of $108.33 billion, a P/E ratio of 26.77 and a beta of 1.02.

Medtronic PLC (NYSE:MDT) last posted its quarterly earnings results on Tuesday, August 22nd. The medical technology company reported $1.12 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.08 by $0.04. The firm had revenue of $7.39 billion for the quarter, compared to analyst estimates of $7.44 billion. Medtronic PLC had a return on equity of 12.92% and a net margin of 13.75%. The business’s quarterly revenue was up 3.1% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.03 EPS. On average, analysts anticipate that Medtronic PLC will post $4.76 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Friday, October 20th. Shareholders of record on Friday, September 29th will be given a dividend of $0.46 per share. This represents a $1.84 annualized dividend and a dividend yield of 2.31%. The ex-dividend date is Thursday, September 28th. Medtronic PLC’s dividend payout ratio (DPR) is 61.95%.

TRADEMARK VIOLATION NOTICE: This article was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this article on another site, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The original version of this article can be viewed at https://www.thecerbatgem.com/2017/08/29/medtronic-plc-mdt-position-decreased-by-parkwood-llc.html.

A number of research firms recently commented on MDT. UBS AG reaffirmed a “buy” rating and issued a $95.00 target price (up from $94.00) on shares of Medtronic PLC in a research report on Tuesday, May 30th. Oppenheimer Holdings, Inc. reaffirmed a “buy” rating and issued a $92.00 target price on shares of Medtronic PLC in a research report on Tuesday, August 22nd. Jefferies Group LLC reiterated a “buy” rating and set a $103.00 price target on shares of Medtronic PLC in a research note on Thursday, August 3rd. BMO Capital Markets increased their price target on shares of Medtronic PLC from $87.00 to $94.00 and gave the stock an “outperform” rating in a research note on Tuesday, May 30th. Finally, CIBC reiterated a “buy” rating on shares of Medtronic PLC in a research note on Friday, May 26th. Three investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and thirteen have assigned a buy rating to the stock. Medtronic PLC has a consensus rating of “Hold” and a consensus price target of $88.78.

In other Medtronic PLC news, EVP Bryan C. Hanson sold 12,000 shares of the business’s stock in a transaction that occurred on Monday, July 17th. The stock was sold at an average price of $88.57, for a total transaction of $1,062,840.00. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Richard H. Anderson purchased 5,600 shares of the stock in a transaction on Wednesday, June 21st. The shares were bought at an average cost of $88.90 per share, for a total transaction of $497,840.00. Following the transaction, the director now directly owns 71,910 shares in the company, valued at $6,392,799. The disclosure for this purchase can be found here. 0.25% of the stock is owned by insiders.

About Medtronic PLC

Medtronic Public Limited Company (Medtronic) is a medical technology and services company. The Company develops, manufactures and markets its medical devices and technologies to hospitals, physicians, clinicians and patients in approximately 160 countries. The Company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group.

Institutional Ownership by Quarter for Medtronic PLC (NYSE:MDT)

Receive News & Stock Ratings for Medtronic PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic PLC and related stocks with our FREE daily email newsletter.